These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21293948)

  • 1. Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland.
    Bailey B
    Ir J Med Sci; 2011 Jun; 180(2):337-41. PubMed ID: 21293948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?
    Curtiss FR
    J Manag Care Pharm; 2007 Apr; 13(3):287-9. PubMed ID: 17407397
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacoeconomic considerations in the treatment of multiple sclerosis.
    Sharac J; McCrone P; Sabes-Figuera R
    Drugs; 2010 Sep; 70(13):1677-91. PubMed ID: 20731475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C; Aloi JJ
    Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics.
    Rudick RA
    Arch Neurol; 1999 Sep; 56(9):1079-84. PubMed ID: 10488808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.
    Menzin J; Caon C; Nichols C; White LA; Friedman M; Pill MW
    J Manag Care Pharm; 2013; 19(1 Suppl A):S24-40. PubMed ID: 23383731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis.
    Tappenden P; Chilcott JB; Eggington S; Oakley J; McCabe C
    Health Technol Assess; 2004 Jun; 8(27):iii, 1-78. PubMed ID: 15215017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
    Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
    Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents.
    Amato MP
    Expert Opin Pharmacother; 2004 Oct; 5(10):2115-26. PubMed ID: 15461547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007.
    Kunze AM; Gunderson BW; Gleason PP; Heaton AH; Johnson SV
    J Manag Care Pharm; 2007; 13(9):799-806. PubMed ID: 18062731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newer long-term treatments for multiple sclerosis.
    Pryse-Phillips W
    Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
    Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
    J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
    Sabanov AV; Luneva AV; Matveev NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(5):65-9. PubMed ID: 24988963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
    Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
    Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
    Clegg A; Bryant J; Milne R
    Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743
    [No Abstract]   [Full Text] [Related]  

  • 20. Interferon beta in multiple sclerosis.
    Richards RG
    BMJ; 1996 Nov; 313(7066):1159. PubMed ID: 8916730
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.